CN103585152A - Application of Caesanines D in medicament for treating rhinitis - Google Patents
Application of Caesanines D in medicament for treating rhinitis Download PDFInfo
- Publication number
- CN103585152A CN103585152A CN201310607649.5A CN201310607649A CN103585152A CN 103585152 A CN103585152 A CN 103585152A CN 201310607649 A CN201310607649 A CN 201310607649A CN 103585152 A CN103585152 A CN 103585152A
- Authority
- CN
- China
- Prior art keywords
- caesanines
- rhinitis
- medicament
- present
- rat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a Caesanines D for treating immune-inflammation, for preparing a medicament for curing immune-inflammation, and particularly for preparing a medicament for curing rhinitis. Terfenadine and diclofenac sodium are taken as control, Caesanines D is explicit in curative effect and is issued for the first time, because of the novel framework type and the high rhinitis treatment activity, Caesanines D has outstanding substantive characteristics, and meanwhile the prevention and the treatment on rhinitis are greatly improved.
Description
Technical field
The present invention relates to the new purposes of Compound C aesanines D, relate in particular to the application of Caesanines D in preparation treatment rhinitis medicine.
Background technology
Rhinitis is common clinical and frequently-occurring disease, and the generation of rhinitis is main relevant with anaphylaxis, belongs to the category of immune inflammation.At present, treatment rhinitis mainly adopts the Claritins such as the antihistamine drug such as teldane or tranilast, ketotifen, and these medicines are poor or invalid to the chronicity of rhinitis and the curative effect of repeatedly showing effect.Therefore, definite ingredients, quality controllable and safely and efficiently micromolecular compound aspect development treatment of rhinitis medicine, there is potential value.
The Compound C aesanines D the present invention relates to is one and within 2013, delivers (Jingyu Zhang, et al., Caesanines AD, New Cassane Diterpenes with Unprecedented N Bridge from Caesalpinia sappan.Organic Letters, 2013, 15 (18): 4726 – 4729.) noval chemical compound, this compound has brand-new framework types, find antibiotic (the Jingyu Zhang of its energy, et al., Caesanines AD, New Cassane Diterpenes with Unprecedented N Bridge from Caesalpinia sappan.Organic Letters, 2013, 15 (18): 4726 – 4729.), the purposes of the Caesanines D the present invention relates in preparation treatment rhinitis medicine belongs to open first.
Summary of the invention
The object of the invention is to, according to not finding that it has the present situation of the report of anti-rhinitis activity in existing Caesanines D research, provides the application of Caesanines D in preparing anti-rhinitis medicament thing.
Described Compound C aesanines D, structure is as shown in formula I:
Formula I
Caesanines D10,20mg/kg oral administration, raises inhibitedly to scratch nose, sneeze reaction and nasal cavity vascular permeability of rat due to antigen (ovalbumin) and histamine, therefore, can be used for the medicine of preparation treatment rhinitis.
The purposes of Caesanines D in preparation treatment rhinitis medicine belongs to open first, because framework types belongs to brand-new framework types, and its treatment rhinitis is active strong, possesses outstanding substantive distinguishing features, the control for rhinitis simultaneously obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The preparation method of Compound C aesanines D involved in the present invention is referring to document (Jingyu Zhang, et al., Caesanines AD, New Cassane Diterpenes with Unprecedented N Bridge from Caesalpinia sappan.Organic Letters, 2013,15 (18): 4726 – 4729.), prepare according to the method described above Compound C aesanines D.
Embodiment 1: the preparation of Compound C aesanines D tablet involved in the present invention:
Get 5 and digest compound Caesanines D, add 195 grams, dextrin, mix, conventional tabletting is made 1000.
Embodiment 2: the preparation of Compound C aesanines D capsule involved in the present invention:
Get 5 and digest compound Caesanines D, add 180 grams of starch, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
Experimental example 1, Caesanines D of the present invention cause the impact of rat allergic rhinitis on ovalbumin
Male SD rat, body weight 180～220g, lumbar injection ovalbumin 1mg and gel aluminum hydroxide 10mg, inject the next day of thereafter 1 time, totally 7 times.From the 14th day, begin, splash into 1mg/ml ovalbumin normal saline solution 10ul, totally 7 time at rat both sides nasal cavity every day.After last instils, observe at once rat sneeze in 30 minutes and wipe the number of times of nose, trial drug is in ovalbumin last first 1 hour oral the giving of instiling.
Table 1 Caesanines D of the present invention causes the impact (x ± SD) of rat allergic rhinitis on ovalbumin
With matched group comparison, * * P<0.01*P<0.05
From table 1, Caesanines D(10,20mg/kg) obviously suppress sneeze and the nose reaction of scratching of allergic rhinitis rat due to ovalbumin.Teldane 10mg/kg also presents significant inhibitory action.
The impact of the rat rhinitis that experimental example 2, Caesanines D of the present invention cause histamine
Male SD rat, body weight 180～220g, orally gives after trial drug 1 hour, and both sides nasal cavity splashes into 1M histamine normal saline solution 10ul, observes rat sneeze in 30 minutes and wipes the number of times of nose.
Table 2 Caesanines D of the present invention causes the impact (x ± SD) of rat rhinitis on histamine
With matched group comparison, * * P<0.01*P<0.05
From table 2, Caesanines D(10,20mg/kg of the present invention) obviously reduce the sneeze number of times of rhinitis rat due to histamine, to scratching, nose reaction is inhibition trend.Teldane 10mg/kg is significant inhibitory action.
Conclusion: Caesanines D oral administration, inhibited to scratch nose, sneeze reaction of rat due to antigen (ovalbumin) and histamine, therefore, can be used for the medicine of preparation treatment rhinitis.
Claims (1)
- The application of 1.Caesanines D in treatment rhinitis medicine, described Compound C aesanines D structure is as shown in formula I:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310607649.5A CN103585152A (en) | 2013-11-26 | 2013-11-26 | Application of Caesanines D in medicament for treating rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310607649.5A CN103585152A (en) | 2013-11-26 | 2013-11-26 | Application of Caesanines D in medicament for treating rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103585152A true CN103585152A (en) | 2014-02-19 |
Family
ID=50075606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310607649.5A Pending CN103585152A (en) | 2013-11-26 | 2013-11-26 | Application of Caesanines D in medicament for treating rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103585152A (en) |
-
2013
- 2013-11-26 CN CN201310607649.5A patent/CN103585152A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| JINGYU ZHANG等: "Caesanines A-D, New Cassane Diterpenes with Unprecedented N Bridge from Caesalpinia sappan", 《ORGANIC LETTERS》 * |
| 董震等: "金黄色葡萄球菌超抗原和慢性鼻黏膜炎症", 《中国耳鼻咽喉头颈外科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103585150B (en) | Use of Nitrosporeusines A in drugs for treating rhinitis | |
| CN103585152A (en) | Application of Caesanines D in medicament for treating rhinitis | |
| CN105362274A (en) | Application of biscarpamontamine A in preparation of rhinitis pharmaceuticals | |
| CN103330712A (en) | Application of Myriberine A in preparation of a medicine for treating rhinitis | |
| CN103463007A (en) | Application of racemosins A in preparation of medicine treating rhinitis | |
| CN102872034B (en) | Application of Gypensapogenin B in medicaments for treating rhinitis | |
| CN103494826B (en) | The application of Phyllanthoid A in preparation treatment rhinitis medicine | |
| CN103751170B (en) | The application of Trigoxyphin K in treatment rhinitis medicine | |
| CN103638007A (en) | Application of Hippolachnin A in medicine for treatment of rhinitis | |
| CN103462999A (en) | Application of Neonectrolide A in preparing medicament for treating rhinitis | |
| CN105287545A (en) | Applications of Strynuxlines A in preparation of rhinitis treatment drugs | |
| CN105456246A (en) | Application of Lathyranone A in preparation of drug for treating rhinitis | |
| CN105287495A (en) | Application of Sphenostylisins C in preparation of drugs used for treating rhinitis | |
| CN103271932A (en) | Applications of compound in preparing drug for treating rhinitis | |
| CN106491617A (en) | Applications of the Friedolanostanes in treatment rhinitis medicine is prepared | |
| CN102988390B (en) | Application of Houttuynoid C for preparing medicine for treating rhinitis | |
| CN102988393B (en) | Application of Houttuynoid B for preparing medicine for treating rhinitis | |
| CN105125533A (en) | Medicine for treating rhinitis and application thereof | |
| CN103372006B (en) | The application of Chukrasone B in preparation treatment rhinitis medicine | |
| CN103393699B (en) | The application of Chukrasone A in preparation treatment rhinitis medicine | |
| CN106551936A (en) | One kind treats rhinitis medicine and its application | |
| CN106389404A (en) | Applications of Linderolide H in preparing medicines for treating rhinitis | |
| CN110327345B (en) | Application of phosphodiesterase 9A inhibitor for preventing and treating ischemic cerebral apoplexy | |
| CN107865862A (en) | Apigenin is preparing the application in treating rhinitis medicine | |
| CN103127078A (en) | Application of Aphanamixoid A to rhinitis treatment medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140219 |